Published in Thorax on July 29, 2005
Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. Ann Thorac Med (2014) 1.40
Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol (2008) 1.38
Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J (2011) 1.36
Pulmonary arterial hypertension: an update. Neth Heart J (2011) 1.26
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol (2010) 1.18
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag (2009) 0.94
Epoprostenol treatment in children with severe pulmonary hypertension. Heart (2006) 0.93
Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ (2011) 0.89
Treatment of pulmonary hypertension. Med Sci Monit (2012) 0.87
Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol (2010) 0.84
Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ J (2009) 0.83
Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag (2014) 0.82
A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost. Pulm Circ (2013) 0.80
Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther (2014) 0.79
Pulmonary arterial hypertension: advances in pathophysiology and management. Indian J Pharmacol (2012) 0.79
Improving survival in idiopathic pulmonary arterial hypertension: revisiting the "kingdom of the near-dead". Thorax (2005) 0.78
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag (2010) 0.77
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2008) 0.77
[Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment]. Z Rheumatol (2006) 0.76
Recent strategies in treatment of pulmonary arterial hypertension, a review. Glob J Health Sci (2015) 0.76
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study. Pharmacoeconomics (2016) 0.75
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.75
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation (2002) 4.42
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 1.71
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol (1988) 16.45
Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 12.35
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med (1996) 11.76
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med (1998) 7.08
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med (1995) 6.97
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet (2008) 5.01
Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet (2000) 4.42
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83
Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol (2000) 3.58
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2001) 3.51
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum (2004) 3.46
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA (1997) 3.35
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J (2010) 2.90
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J (2005) 2.82
Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet (2000) 2.82
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med (1994) 2.75
Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest (2000) 2.64
Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest (2001) 2.59
Reliability of skin involvement measures in scleroderma. The UK Scleroderma Study Group. Br J Rheumatol (1992) 2.58
Population health and health care use: an information system for policy makers. Milbank Q (1996) 2.54
BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet (2000) 2.51
Primary pulmonary hypertension. Lancet (1998) 2.47
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J (2009) 2.41
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol (2001) 2.35
Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest (1997) 2.29
Career differences between primary care and traditional trainees in internal medicine and pediatrics. Ann Intern Med (1992) 2.28
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Evaluation of mosaic pattern areas in HRCT with Min-IP reconstructions in patients with pulmonary hypertension: could this evaluation replace lung perfusion scintigraphy? Eur J Radiol (2010) 2.27
Primary pulmonary hypertension. Chest (1993) 2.26
Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med (2000) 2.25
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J (1998) 2.14
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax (2005) 2.03
Primary pulmonary hypertension and fenfluramine use. Br Heart J (1993) 2.02
Isolation and characterization of the inositol cyclic phosphate products of polyphosphoinositide cleavage by phospholipase C. Physiological effects in permeabilized platelets and Limulus photoreceptor cells. J Biol Chem (1985) 1.98
Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J (2005) 1.98
myo-Inositol polyphosphate may be a messenger for visual excitation in Limulus photoreceptors. Nature (1984) 1.96
Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol (2001) 1.94
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med (2007) 1.86
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J (2009) 1.85
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation (1998) 1.80
Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J (2006) 1.78
Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med (1980) 1.77
Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation. Lancet (1997) 1.76
[Guidelines for the diagnosis and treatment of pulmonary hypertension]. Rev Mal Respir (2010) 1.74
Chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 1.74
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol (1999) 1.71
High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest (1999) 1.70
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol (1993) 1.67
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65